摘要
目的探讨左西孟旦联合托伐普坦治疗心力衰竭的疗效,为临床治疗不同类型心力衰竭提供参考。方法将急性心力衰竭和慢性心力衰竭患者共367例分为两组,观察组(197例)行左西孟旦联合托伐普坦治疗,对照组(170例)行心内科常规治疗。结果观察组较对照组,改善患者射血分数[(39.84±4.21)%>(36.74±3.53)%)]和每搏心输出量[(80.64±12.41)m L>(72.30±9.84)m L]均有显著优势(P<0.05);观察组中急性心力衰竭患者和慢性心力衰竭患者的疗效差异无统计学意义(P>0.05)。结论左西孟旦联合托伐普坦治疗急性心力衰竭和慢性心力衰竭均有显著效果,与常规方法相比有显著优势。
Objective To investigate the efficacy of levosimendan combined with tolvaptan in treating heart failure, to provide theoretical guidance for the clinical treatment of different types of heart failure. Methods 367 cases of acute and chronic heart failure patients were selected and divided into the observation group and the control group. The observation group received levosimendan combined with tolvaptan, the control group received conventional cardiology treatment. The clinical efficacy, cardiac function recovery, and NYHA of the two groups were analyzed to compare the two methods. Results Compared with the control group, the improvement of patient ejection fraction in the observation group was better [（39.84±4.21）% 〉 （36.74±3.53）%, P 〈 0.05], and the stroke volume and cardiac output of the observation group had significant advantage [（80.64 ±12.41）mL 〉 （72. 30 ±9.84）mL, P 〈 0.05]. The treatment of pa- tients with acute heart failure and chronic heart failure had no significant difference in efficacy（ P 〉 0.05）. Conclusion Levosimendan combined with tolvaptan in treating different types of heart failure has significant effect, and has obvious advantages compared with the conventional methods.
出处
《中国药业》
CAS
2015年第19期37-38,共2页
China Pharmaceuticals
